- Home
- CHPT vs MREO Comparison
CHPT vs MREO Comparison
Compare CHPT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- MREO
- Stock Information
- Founded
- CHPT 2007
- MREO 2015
- Country
- CHPT United States
- MREO United Kingdom
- Employees
- CHPT N/A
- MREO N/A
- Industry
- CHPT Industrial Specialties
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- MREO Health Care
- Exchange
- CHPT Nasdaq
- MREO Nasdaq
- Market Cap
- CHPT 468.9M
- MREO 482.5M
- IPO Year
- CHPT N/A
- MREO N/A
- Fundamental
- Price
- CHPT $0.76
- MREO $2.85
- Analyst Decision
- CHPT Hold
- MREO Strong Buy
- Analyst Count
- CHPT 13
- MREO 6
- Target Price
- CHPT $2.46
- MREO $7.83
- AVG Volume (30 Days)
- CHPT 33.1M
- MREO 882.2K
- Earning Date
- CHPT 03-04-2025
- MREO 03-26-2025
- Dividend Yield
- CHPT N/A
- MREO N/A
- EPS Growth
- CHPT N/A
- MREO N/A
- EPS
- CHPT N/A
- MREO N/A
- Revenue
- CHPT $431,026,000.00
- MREO $1,000,000.00
- Revenue This Year
- CHPT N/A
- MREO N/A
- Revenue Next Year
- CHPT $13.02
- MREO N/A
- P/E Ratio
- CHPT N/A
- MREO N/A
- Revenue Growth
- CHPT N/A
- MREO N/A
- 52 Week Low
- CHPT $0.66
- MREO $2.53
- 52 Week High
- CHPT $2.44
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- CHPT 35.80
- MREO 38.17
- Support Level
- CHPT $0.66
- MREO $2.82
- Resistance Level
- CHPT $0.86
- MREO $2.99
- Average True Range (ATR)
- CHPT 0.07
- MREO 0.13
- MACD
- CHPT 0.00
- MREO 0.01
- Stochastic Oscillator
- CHPT 31.37
- MREO 14.74
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).